- C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
- C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
- C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
More ▼
Key statistics
On Wednesday, C4 Therapeutics Inc (CCCC:NSQ) closed at 5.94, 460.38% above the 52 week low of 1.06 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.35 |
---|---|
High | 6.51 |
Low | 5.80 |
Bid | 5.94 |
Offer | 6.10 |
Previous close | 6.48 |
Average volume | 2.06m |
---|---|
Shares outstanding | 68.81m |
Free float | 60.72m |
P/E (TTM) | -- |
Market cap | 445.86m USD |
EPS (TTM) | -2.37 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 21:00 BST.
More ▼